Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07288138

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of ECC4703, ECC0509, and Their Combination in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

Led by Eccogene · Updated on 2026-06-05

160

Participants Needed

58

Research Sites

2 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the effects of two drugs, ECC4703 and ECC0509, alone and in combination, on reducing liver fat in adults with presumed Metabolic Dysfunction-associated Steatohepatitis (MASH). This Phase 2a, randomized, double-blind, placebo-controlled study aims to understand how different doses impact liver fat as measured by MRI proton density fat fraction (MRI-PDFF) at 12 weeks. Participants will be randomly assigned to one of six groups: placebo, low or high dose ECC4703, low or high dose ECC0509, or a combination of high doses of both drugs. All treatments are given as oral capsules. The main treatment period lasts 12 weeks, during which the impact on liver fat and other related health markers will be assessed. During the study, participants will undergo various assessments including MRI scans to measure liver fat, blood tests to monitor liver enzymes and metabolic markers, and other biomarker evaluations at baseline and Week 12. Safety and drug levels will be monitored throughout. The study involves close follow-up to track changes in liver fat content and related health outcomes over the 12-week treatment period.

CONDITIONS

Brief Title

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults between 18 and 75 years of age who can provide informed consent and follow study procedures
  • Diagnosis of presumed MASH based on liver biopsy within 180 days showing NAFLD activity score of 3 or more and fibrosis score F1-3, or FibroScan CAP over 280 dB/m with metabolic risk factors
  • Evidence of hepatic steatosis with FibroScan liver stiffness measurement over 7 kPa and under 20 kPa and MRI-PDFF over 8% at screening
  • Body mass index over 25 kg/m² to under 50 kg/m² (non-Asian); or over 23.0 to under 50.0 kg/m² (Asian)
  • Alanine aminotransferase (ALT) 60 U/L or higher at first screening visit with stable ALT and AST during screening
  • Estimated glomerular filtration rate (eGFR) 60 mL/min/1.73m² or higher
  • Stable body weight (no more than 5% change) for at least 6 months before screening
  • Willingness to comply with contraception requirements if applicable
  • Ability to safely participate and complete MRI and biomarker assessments as judged by investigator
Not Eligible

You will not qualify if you...

  • Chronic liver diseases other than MASLD/MASH, including alcoholic liver disease, autoimmune hepatitis, cholestatic disease, genetic liver diseases, or drug-induced liver injury
  • Presence of cirrhosis or portal hypertension based on liver histology or imaging
  • ALT and/or AST greater than 5 times the upper limit of normal or alkaline phosphatase (ALP) over 2 times upper limit at screening
  • Significant thyroid or adrenal dysfunction, including uncontrolled hypo- or hyperthyroidism or adrenal disorders
  • Type 1 diabetes, HbA1c over 9.5%, or unstable type 2 diabetes with medication changes within 90 days
  • Use of medications affecting liver fat or fibrosis within specified washout periods
  • Significant alcohol use within 1 year prior to screening
  • Recent cardiovascular events such as heart attack, stroke, unstable angina, severe heart failure, or uncontrolled arrhythmia
  • Current or recent serious psychiatric illness including psychosis or active suicidal ideation within 5 years
  • Pregnancy, breastfeeding, MRI contraindications, or other safety concerns preventing study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 12 weeks

Participants receive oral capsules of ECC4703, ECC0509, their combination, or placebo to evaluate effects on liver fat content and other health measures.

Visits on Day 1, and Weeks 2, 4, 6, 8, and 12 for assessments and dosing

Trial Site Locations

Total: 58 locations

1

Arizona Liver Health

Chandler, Arizona, United States, 85224

Actively Recruiting

2

Arizona Liver Health - Peoria

Peoria, Arizona, United States, 85381

Actively Recruiting

3

Adobe Clinical Research, LLC

Tucson, Arizona, United States, 85712

Actively Recruiting

4

Arizona Liver Health - Tucson

Tucson, Arizona, United States, 85712

Actively Recruiting

5

Arkansas Gastroenterology, P.A

Little Rock, Arkansas, United States, 71913

Actively Recruiting

6

ARcare Center for Clinical Research

Little Rock, Arkansas, United States, 77205

Actively Recruiting

7

Om Research

Apple Valley, California, United States, 92307

Actively Recruiting

8

ARK Clinical Research - Fountain Valley

Fountain Valley, California, United States, 92708

Actively Recruiting

9

Ark Clinical Research

Long Beach, California, United States, 90815

Actively Recruiting

10

Knowledge Research Center

Orange, California, United States, 92868

Actively Recruiting

11

Synergy Healthcare

Bradenton, Florida, United States, 33511

Actively Recruiting

12

Synergy Healthcare

Bradenton, Florida, United States, 34209

Actively Recruiting

13

Health Awareness, Inc.

Jupiter, Florida, United States, 33458

Actively Recruiting

14

Evolution Clinical Trials

Miami, Florida, United States, 33122

Actively Recruiting

15

Floridian Clinical Research, LLC

Miami Lakes, Florida, United States, 33016

Actively Recruiting

16

Ocala GI Research

Ocala, Florida, United States, 34471

Actively Recruiting

17

Progressive Medical Research

Port Orange, Florida, United States, 32127

Actively Recruiting

18

ClinCloud, LLC

Viera, Florida, United States, 32940

Actively Recruiting

19

Metabolic Research Institute

West Palm Beach, Florida, United States, 33401

Actively Recruiting

20

CenExel - iResearch

Decatur, Georgia, United States, 30030

Actively Recruiting

21

Gastrointestinal Specialists of Georgia, PC

Marietta, Georgia, United States, 30060

Actively Recruiting

22

Digestive Research Alliance of Michiana

South Bend, Indiana, United States, 46635

Actively Recruiting

23

Tandem Clinical Research

Covington, Louisiana, United States, 70433

Actively Recruiting

24

Tandem Clinical Research

Houma, Louisiana, United States, 70360

Actively Recruiting

25

Tandem Clinical Research GI, LLC

Marrero, Louisiana, United States, 70072

Actively Recruiting

26

Tandem Clinical Research

Metairie, Louisiana, United States, 70006

Actively Recruiting

27

Delta Research Partners

Monroe, Louisiana, United States, 71201

Actively Recruiting

28

Louisiana Research Center, LLC

Shreveport, Louisiana, United States, 71105

Actively Recruiting

29

Delta Research Partners, LLC

West Monroe, Louisiana, United States, 71291

Actively Recruiting

30

Mid-Atlantic GI Research

Greenbelt, Maryland, United States, 20770

Actively Recruiting

31

Gastrointestinal Associates

Columbia, Missouri, United States, 65201

Actively Recruiting

32

Gateway GI Research, LLC

St Louis, Missouri, United States, 63141

Actively Recruiting

33

Jubilee Clinical Research, Inc

Las Vegas, Nevada, United States, 89106

Actively Recruiting

34

Premier Health Research

Sparta, New Jersey, United States, 07871

Actively Recruiting

35

Coastal Research Institute

Fayetteville, North Carolina, United States, 28304

Actively Recruiting

36

Akron Gastro Research

Akron, Ohio, United States, 44333

Actively Recruiting

37

Digestive Specialists

Dayton, Ohio, United States, 45414

Actively Recruiting

38

DSI Research

Springboro, Ohio, United States, 45066

Actively Recruiting

39

Columbia Gastroenterology Associates, Llc

Columbia, South Carolina, United States, 29204

Actively Recruiting

40

Pinnacle Clinical Research

Austin, Texas, United States, 78757

Actively Recruiting

41

Bellaire Clinical Research

Bellaire, Texas, United States, 77401

Actively Recruiting

42

South Texas Research Institute (STRI) - Brownsville

Brownsville, Texas, United States, 78520

Actively Recruiting

43

Pinnacle Clinical Research

Corpus Christi, Texas, United States, 78404

Actively Recruiting

44

South Texas Research Institute (STRI)

Edinburg, Texas, United States, 78539

Actively Recruiting

45

Dallas Research Institute, LLC

Farmers Branch, Texas, United States, 75234

Actively Recruiting

46

Care United Research

Forney, Texas, United States, 75126

Actively Recruiting

47

Evidentis Clinical Research

Fort Worth, Texas, United States, 76104

Actively Recruiting

48

Pinnacle Clinical Research - Georgetown

Georgetown, Texas, United States, 78626

Actively Recruiting

49

Houston Research Institute - Medical Center

Houston, Texas, United States, 770004

Actively Recruiting

50

Houston Research Institute

Houston, Texas, United States, 77079

Actively Recruiting

51

Houston Research Institute - Pasadena

Pasadena, Texas, United States, 77505

Actively Recruiting

52

Quality Research, Inc.

San Antonio, Texas, United States, 78209

Actively Recruiting

53

Pinnacle Clinical Research - South San Antonio

San Antonio, Texas, United States, 78222

Actively Recruiting

54

Pinnacle Clinical Research

San Antonio, Texas, United States, 78229

Actively Recruiting

55

Sugarland Medical Associates (Sma)

Sugar Land, Texas, United States, 77478

Actively Recruiting

56

Digestive Research of Central Texas

Waco, Texas, United States, 76712

Actively Recruiting

57

Digestive Health Research of North Texas, LLC

Wichita Falls, Texas, United States, 76301

Actively Recruiting

58

GI Select Health Research

Richmond, Virginia, United States, 23236

Actively Recruiting

Loading map...

Research Team

E

Eccogene Clinical Trials

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

6

Similar Trials

A Phase 2, Randomized, Double-blinded, Placebo-controlled St...

Metabolic Dysfunction-Associated Steatohepatitis

Actively Recruiting

35 locations

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Stud...

Metabolic Dysfunction-Associated Steatotic Liver Disease

Actively Recruiting

3 locations

A Phase I, Open-Label, Randomized, Single-Dose, Crossover St...

Metabolic Dysfunction-Associated Steatohepatitis

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here